Daratumumab demonstrated activity in the treatment of AL amyloidosis in two recently concluded phase II clinical trials in relapsed and refractory patients. Its role in upfront therapy is under evaluation in a phase III study. In this report we evaluated the safety and efficacy of 28-day cycles of daratumumab (single agent or combined with bortezomib or lenalidomide) in 72 previously treated patients with multiple myeloma and AL amyloidosis. Fifty (69%) were refractory to the last line of therapy. After 8 infusions of daratumumab, 59 patients (82%) achieved a hematologic response, with 12 (16%) complete responses and 30 (42%) very good partial responses. After 16 infusions, the quality of response improved with 22 patients (30%) achieving complete response and 21 (29%) attaining very good partial response. Cardiac response was observed in 11 of 37 evaluable patients (29%) and renal response in 23 of 38 patients (60%). Daratumumab is highly effective in heavily pretreated patients with relapsed/refractory AL amyloidosis and high bone marrow plasma cell burden. Renal responses, which are usually rare in this setting, were frequently observed. This article is protected by copyright. All rights reserved.
You may also be interested in...
Daratumumab therapy addition improved response in systemic immunoglobulin light-chain amyloidosis
Treatment for treating disease-related splenomegaly or symptoms in myelofibrosis not recommended in NICE draft guidance
Clinical trial evidence is uncertain and it is unlikely that collecting more data in the Cancer Drugs Fund would resolve the uncertainties, according to the draft guidance.
Therapeutic anticoagulation increases bleeding risk without improvements in clinical outcomes in patients admitted for COVID-19 and elevated D-dimer